Abstract
Since chemotherapy of metastatic colorectal cancer (CRC) is palliative by definition, hepatic resection is the only potentially curative option for liver metastases. The demonstration of a curative potential of liver surgery in liver-limited stage IV CRC abrogated the need for randomized trials to address the value of surgery in the setting of resectable liver metastasis; in fact, such trials would be unethical. Methods to improve resectability of metastases and long-term outcome utilizing chemotherapy are explored in this chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984;199:502–508.
Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240:438–447; discussion 447-450.
Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309–318; discussion 318-321.
Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77:1254–1262.
Headrick JR, Miller DL, Nagorney DM, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001;71:975–979; discussion 979–980.
Pawlik TM, Scoggins CR, Thomas MB, et al. Advances in the surgical management of liver malignancies. Cancer J 2004;10:74–87.
Jarnagin WR, Bach AM, Winston CB, et al. What is the yield of intraoperative ultrasonography during partial hepatectomy for malignant disease? J Am Coll Surg 2001;192:577–583.
Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818–825; discussion 825–827.
Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–2351.
Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039–2048.
Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005;352:734–735.
Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005;5 Suppl 1:38S–46S.
Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311–1319.
Kelly RJ, Kemeny NE, Leonard GD. Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer. Clin Colorectal Cancer 2005;5:166–174.
Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509–520; discussion 520–522.
Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001;8:347–353.
Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II study. J Clin Oncol 2005;23:9243–9249.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005;23:4853–4855.
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–345.
DÃaz Rubio E, Tabernero J, van Cutsem E, et al. Cetuximab in combination with oxaliplatin/ 5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. J Clin Oncol 2005;23:254S (Suppl, Abstract 3535).
Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?; Ann Surg 2004;240:052–1061; discussion 1061–1064.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Grothey, A., Alberts, S.A. (2007). Rationale for Adjuvant and Neoadjuvant Chemotherapy in the Resection of Liver Metastases. In: Markman, M., Saltz, L.B. (eds) Colorectal Cancer. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-215-1_10
Download citation
DOI: https://doi.org/10.1007/978-1-59745-215-1_10
Publisher Name: Humana Press
Print ISBN: 978-1-58829-751-8
Online ISBN: 978-1-59745-215-1
eBook Packages: MedicineMedicine (R0)